In conclusion, while this study did not find significant associations between baseline prolactin levels and key clinical outcomes or inflammatory markers in COVID-19 patients, it remains a pioneering effort in evaluating prolactin as a potential biomarker for disease severity. Here, PRL is linked to COVID-19.